Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Michail Ignatiadis MD, PhD

Michail Ignatiadis MD, PhD

Director of the Breast Medical Oncology Clinic & Program, Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium

Michail Ignatiadis, MD, PhD, is the Director of the Breast Medical Oncology Clinic & Program, Medical Oncology Department, Jules Bordet Institute (IJB) and associate professor at the Université Libre de Bruxelles, Belgium. Since January 2021 is the chair of the breast cancer group of the EORTC. He is also leading the Academic Trials Promoting Team (ATPT) and he is member of the Executive and Research Boards of IJB since October 2016. From June 2018 to January 2021, he served in the Board of Directors of the EORTC as the chair of the clinical research division. He has been involved in many investigator initiated trials (IITs) sponsored by IJB at different stages of their development. He has been member of the Independent data monitoring committees for international trials and study chair of several IITs and industry sponsored trials.


Speaking fee/honoraria from Novartis, Seattle Genetics; research grant to my Institution from Pfizer, Roche, Inivata Inc, Natera Inc, Gilead; meeting/travel grants from Roche, AstraZeneca, Gilead (all outside the submitted work).